A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988 · cited 2×
“Major depressive disorder (MDD) is a debilitating mental illness that affects millions of people worldwide leading to severe health and socioeconomic consequences (Kessler et al., 2003).”
BackgroundRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“Another limitation of current monoamine-based antidepressants was high-lighted in the large well-known trial; sequenced treatment alternative to relieve depression (STAR n D Trial) (Rush et al., 2006a, 2006b; Trivedi et al., 2006; Nierenberg et al., (2006); Rush, 2006c; Fava et al., 2006).”
BackgroundAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The Glutamate Receptor Ion Channels
Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01394-2 · Cited by 3,554 · cited 1×
“NMDA receptors are tetrameric proteins composed of 2 NR1 subunits and 2 NR2 subunits (Dingledine et al., 1999).”
BackgroundAssessment of suicidal intention: The Scale for Suicide Ideation.
Beck, A. T., Kovacs, M., & Weissman, A. (1979) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.47.2.343 · Cited by 3,419
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 11×
“These signalling events activate mTOR (mammalian target of rapamycin), leading to increased synaptic proteins and spine densities (in preclinical studies of rat prefrontal cortices) resulting in synaptogenesis (Li et al., 2010).”
BackgroundInfluentialSüdhof, T. C. (2004) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.041002.131412 · Cited by 2,547
Cited by
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
Witt, K., Potts, J., Hubers, A., Grunebaum, M. F., Murrough, J. W., Loo, C., Cipriani, A., & Hawton, K. (2020) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419883341 · Cited by 202
“Although some reviews investigating the effectiveness of ketamine as an emergency treatment have been conducted, often they include only brief mention of the efficacy of ketamine in reducing suicidal ideation in these populations of patients without specific details (Caddy et al., 2015; McCloud et al., 2015; Naughton…”
BackgroundKetamine and other glutamate receptor modulators for depression in adults
Caddy, C., Amit, B. H., McCloud, T. L., Rendell, J. M., Furukawa, T. A., McShane, R., Hawton, K., & Cipriani, A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011612.pub2 · Cited by 174
Li, C., Chen, M., Lin, W., Hong, C., Yang, B., Liu, R., Tu, P., & Su, T. (2016) · Human Brain Mapping · doi:10.1002/hbm.23085 · Cited by 152
“Low-dose ketamine results in rapid improvement of depressive symptoms (within 1 h) in patients with treatment-resistant depression (TRD) [Mathew et al., 2012; Naughton et al., 2014].”
BackgroundHu, Y.-D., Xiang, Y.-T., Fang, J.-X., Zu, S., Sha, S., Shi, H., Ungvari, G. S., Correll, C. U., Chiu, H. F. K., Xue, Y., et al. (2016) · Psychological Medicine · doi:10.1017/s0033291715002159 · Cited by 146
“However, although ketamine’s effect has been extended by repeated infusions, the results in relapse prevention have been less than promising (aan het Rot et al. 2010; Murrough et al. 2013b; Naughton et al. 2014).”
BackgroundAllen, A. P., Naughton, M., Dowling, J., Walsh, A., Ismail, F., Shorten, G., Scott, L., McLoughlin, D. M., Cryan, J. F., Dinan, T. G., et al. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.06.033 · Cited by 138
Self-citationPham, T. H., Mendez-David, I., Defaix, C., Guiard, B. P., Tritschler, L., David, D. J., & Gardier, A. M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.05.010 · Cited by 136
Ketamine enantiomers in the rapid and sustained antidepressant effects
Muller, J., Pentyala, S., Dilger, J., & Pentyala, S. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316631267 · Cited by 122
Rong, C., Park, C., Rosenblat, J. D., Subramaniapillai, M., Zuckerman, H., Fus, D., Lee, Y. L., Pan, Z., Brietzke, E., Mansur, R. B., et al. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15040771 · Cited by 114
“, mTor, rapamycin), cellular proliferation, and neuroplasticity-promoting intracellular cascades [11,12].”
BackgroundPatrizi, A., Picard, N., Simon, A. J., Gunner, G., Centofante, E., Andrews, N. A., & Fagiolini, M. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.018 · Cited by 100
“PV components including mammalian target of rapamycin (mTOR) pathway, glycogen synthase kinase-3, and eukaryotic elongation factor 2 (63).”
Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults
McCloud, T. L., Caddy, C., Jochim, J., Rendell, J. M., Diamond, P. R., Shuttleworth, C., Brett, D., Amit, B. H., McShane, R., Hamadi, L., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011611.pub2 · Cited by 102
Dean, R. L., Hurducas, C., Hawton, K., Spyridi, S., Cowen, P. J., Hollingsworth, S., Marquardt, T., Barnes, A., Smith, R., McShane, R., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011612.pub3 · Cited by 95
Besteher, B., Gaser, C., & Nenadić, I. (2020) · Neuropsychobiology · doi:10.1159/000501024 · Cited by 83
El Iskandrani, K. S., Oosterhof, C. A., El Mansari, M., & Blier, P. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115573809 · Cited by 75
“…target of rapamycin (mTOR) pathway (Li et al., 2010, 2011) which results in an increase in translation of the brain-derived neurotrophic factor (BDNF) protein (Naughton et al., 2014; Zhou et al., 2013), ultimately leading to enhanced synaptic plasticity and neurotrophic changes (Li et al., 2011).”
BackgroundNogo, D., Jasrai, A. K., Kim, H., Nasri, F., Ceban, F., Lui, L. M. W., Rosenblat, J. D., Vinberg, M., Ho, R., & McIntyre, R. S. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06105-9 · Cited by 54
Broome, M. R., & de Cates, A. (2015) · Journal of Medical Ethics · doi:10.1136/medethics-2015-102812 · Cited by 35
Dornbierer, D. A., Marten, L., Mueller, J., Aicher, H. D., Mueller, M. J., Boxler, M., Kometer, M., Kosanic, D., von Rotz, R., Puchkov, M., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1246892 · Cited by 32
Lago, S. G., Tomasik, J., van Rees, G. F., Ramsey, J. M., Haenisch, F., Cooper, J. D., Broek, J. A., Suarez-Pinilla, P., Ruland, T., Auyeug, B., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0123-4 · Cited by 30
Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression
Ford, N., Ludbrook, G., & Galletly, C. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415590631 · Cited by 23
Nemeroff, C. B. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18010014 · Cited by 19
Shao, J., Meng, L., Yang, Z., Yu, P., Song, L., Gao, Y., Gong, M., Meng, C., & Shi, H. (2020) · NeuroReport · doi:10.1097/wnr.0000000000001415 · Cited by 14
Chen, M., Jin, J., Bi, H., Zhang, Y., Sun, M., Li, X., & Wang, Y. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104502 · Cited by 14
Metadata
- Authors
- Naughton, M., Clarke, G., O′Leary, O. F., Cryan, J. F., & Dinan, T. G.
- Venue
- Journal of Affective Disorders
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 156
- Pages
- 24-35
- ISSN
- 0165-0327 (ISSN-L)
- OpenAlex
- W1999810166
- Cited by
- 190
- References
- 50
- FWCI
- 17.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.